Daniel J. DeAngelo
YOU?
Author Swipe
View article: Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML Open
To improve the tolerability of post-transplant maintenance and outcomes despite poor risk disease genetics, we conducted a phase 1 study of venetoclax/FluBu2 RIC transplantation with tacrolimus/methotrexate GVHD prophylaxis followed by all…
View article: Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Pharmacokinetic analysis of merestinib and LY2874455. A, Merestinib plasma levels were measured at the time points shown and compared between patients receiving single-agent merestinib in Cohort 1 (n=7, black line) and patients receiving m…
View article: Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Survival outcomes for the overall cohort. A, Progression-free survival. B, Overall survival.
View article: Table S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Table S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Any grade adverse event experienced in ≥2 patients.
View article: Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Co-mutation profiles of study subjects. Ordered by frequency. Presence of complex and/or monosomal karyotypes are also denoted in bottom rows.
View article: Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study Open
View article: Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia
Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia Open
Background: The RAS/MAPK signaling pathway is hyperactivated in acute myeloid leukemia (AML). RAS/MAPK signaling converges on the extracellular signal-regulated kinase (ERK) which in turn promotes the transcription of immediate-early genes…
View article: Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay
Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay Open
Introduction Ph-like B-ALL is a poor-risk B-ALL subtype defined by gene expression signatures that resemble the BCR::ABL1-associated transcriptional program in the absence of the BCR-ABL1 oncoprotein. Recent studies have demonstrated that …
View article: Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study
Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study Open
Introduction: Advanced systemic mastocytosis (AdvSM) is a rare clonal hematologic neoplasm mainly driven by D816V-mutant KIT. Avapritinib is a highly potent and selective KIT D816V inhibitor approved at a starting dose of 200 mg once daily…
View article: Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia
Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia Open
Introduction: While newly diagnosed patients (pts) with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy have prolonged survival outcomes with venetoclax plus azacitidine (VEN+AZA) over AZA alone (2-year overall s…
View article: Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab
Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab Open
Introduction: Outcomes for adult patients (pts) with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL) have markedly improved in the era of post-remission consolidation with blinatumomab (blina), a bispecif…
View article: Prevalence and significance of cytoses in clonal hematpoiesis
Prevalence and significance of cytoses in clonal hematpoiesis Open
Introduction Clonal hematopoiesis (CH) is the age-related clonal expansion of hematopoietic progenitor cells, often caused by mutations in genetic drivers of myeloid neoplasia (MN). Clonal hematopoiesis of indeterminate potential (CHIP) an…
View article: Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis Open
Background: Systemic mastocytosis (SM) comprises a spectrum of subtypes characterized by neoplastic mast cell (MC) infiltration of tissues and release of MC mediators. Non-advanced SM (NonAdvSM), including indolent SM (ISM), smoldering SM …
View article: Overcoming CAR T cell resistance in NPM1c and KMT2Ar AML through menin pathway inhibition
Overcoming CAR T cell resistance in NPM1c and KMT2Ar AML through menin pathway inhibition Open
Background. Acute myeloid leukemia (AML) remains a clinical challenge due to high relapse rates and limited durable treatment options, especially in older or unfit patients. Among the most frequent genetic alterations in AML are NPM1 mutat…
View article: Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes
Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes Open
Introduction: In November 2021 ropeginterferon alpha-2B (ropeg) was approved by the FDA for front-line management of PV regardless of thrombotic risk based on the LOW-PV and PROUD/CONTINUATION-PV trials that demonstrated high rates of hema…
View article: Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial
Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial Open
Introduction: Inotuzumab ozogamicin (INO), an anti-CD22 antibody-drug conjugate, can induce a complete remission (CR) in >80% of R/R ALL patients (pts), but remissions are not durable. BCL-2 inhibitors, such as venetoclax (VEN), induce …
View article: Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer
Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer Open
Introduction: Indolent systemic mastocytosis (ISM) is a clonal mast cell disease driven by the KIT D816V mutation in ~95% of cases and is associated with symptoms of mast cell activation and tissue infiltration. It can cause chronic, debil…
View article: No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse Open
Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) portends a dismal prognosis. One approach for reinvigorating a graft-vs-leukemia response is consolidation with donor lymphocyte infusions…
View article: Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia Open
Predictive biomarkers can potentially meet the need for improved drug assignment in acute myeloid leukemia (AML). Fewer than half of AML patients have actionable mutations: consequently, targeted therapy achieves remission in only a fracti…
View article: Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers
Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers Open
Background Demographic enrollment disparities in adult acute leukemia clinical trials limit generalizability and diminish opportunities for minoritized populations to benefit from novel therapies. The distinct natural history and clinical …
View article: Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study
Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study Open
As there are no prospective randomized studies in patients with advanced systemic mastocytosis (AdvSM), we compared clinical outcomes between patients treated with avapritinib in the Phase I EXPLORER (NCT02561988) and Phase II PATHFINDER (…
View article: Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts Open
View article: Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Open
Approximately half of newly diagnosed cases of acute lymphoblastic leukemia (ALL) occur in adults, but adults experience significantly higher rates of treatment failure and treatment-related mortality due to frequent presence of adverse di…
View article: Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis Open
Macrophages in the tumor microenvironment exert potent anti-tumorigenic activity through phagocytosis. Yet therapeutics that enhance macrophage phagocytosis have not improved outcomes in clinical trials for patients with acute myeloid leuk…
View article: Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results Open
Asciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerab…
View article: Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results Open
Data from in vitro and animal studies suggest that asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), synergizes with adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TK…
View article: Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 Open
View article: Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts Open
Measurable residual disease (MRD) is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia (ALL). In addition to its clear prognostic importance, MRD information is increasingly used in clinical decision algorithms to g…
View article: Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes
Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes Open
View article: Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia Open
In acute lymphoblastic leukemia (ALL), the B-cell lymphoma 2 inhibitor venetoclax may enhance the efficacy of chemotherapy, allowing dose reductions. This phase 1b study of venetoclax plus attenuated chemotherapy enrolled 19 patients with …